Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$8.73 - $13.06
Next Earnings Date
May 29 2025 (Estimate)
Next Earnings Date
May 29 2025 (Est.)
Latest price
Market Cap | $7.66B |
EV | $2.96B |
Shares Outstanding | 750.66M |
Beta | 1.25 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $16.75 |
P/E 2025E | - |
P/Revenue 2025E | 54.23x |
Revenue | 73.70% |
EPS | - |
Operating Cash Flow | -11.50% |
Free Cash Flow | -58.90% |
Revenue | -25.70% |
EPS | - |
Operating Cash Flow | -3.40% |
Free Cash Flow | -3.60% |
Gross Margin 2025E | 97.00% |
Net Profit Margin 2025E | -74.80% |
ROE 2025E | -1.50% |
ROCE 2024 | 122.05% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Roivant Sciences Ltd.
ROIV
Sector
Healthcare
Industry
Biotechnology
CEO
Gline, Matthew
Employees
908
Website
roivant.comIPO Date
2020-12-08
Headquarters
50 Broadway, 7th Floor, London, Greater London, SW1H 0DB, United Kingdom
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved